On February 26, 2026, Neurogene Inc. announced that its investigational gene therapy NGN-401, aimed at treating Rett syndrome, has received Breakthrough Therapy Designation from the U.S. FDA. This designation is significant as it may expedite the development and review processes for the therapy.